PDT FOR ORAL CANCER AND LEUCOPLAKIA
INDIA'S EXPERIENCE AT TATA MEMORIAL AND AIIMS
India faces a disproportionate burden of oral pre-malignancy and oral cancer โ largely driven by tobacco and areca nut use. Tata Memorial Hospital and AIIMS Delhi have built world-leading PDT programmes for oral leucoplakia, oral submucous fibrosis, and early oral cancer, with outcomes that are now among the largest published international series.
analyticsAt a Glance
- check_circleIndia has the world's highest oral cancer burden โ driving large PDT programmes at Tata Memorial and AIIMS
- check_circleALA-PDT for oral leucoplakia: 50โ75% complete response; non-surgical; no permanent scarring
- check_circlePDT for early oral SCC in inoperable or recurrent cases: 40โ65% complete response in selected patients
- check_circleOral submucous fibrosis: PDT addressing premalignant changes in this unique Indian condition
Why India Has Developed Unique Oral PDT Expertise
India's disproportionate oral cancer burden has driven the development of specialised oral PDT programmes that are now among the world's most experienced. Understanding this context explains why Indian centres have contributions to this field that exceed those from most Western institutions.
โIndia contributes approximately 25โ30% of global oral cavity cancer cases despite having less than 20% of the world's population. This burden has driven specialist programmes at Tata Memorial and AIIMS that have no equivalent in most Western countries.โ
The Tobacco and Areca Nut Epidemic
India's oral cancer epidemic is driven by tobacco use (smoking and smokeless), areca nut (supari), and betel quid (paan) consumption โ particularly among lower socioeconomic groups. These habits produce a characteristic sequence: oral submucous fibrosis โ oral leucoplakia โ oral erythroplakia โ oral squamous cell carcinoma. The high prevalence of pre-malignant oral lesions creates a large population requiring treatment.
Why Oral Pre-Malignancy Needs PDT
Oral leucoplakia and oral submucous fibrosis are by definition widespread โ affecting large mucosal areas that cannot be surgically excised without functional compromise. PDT applies a field treatment to the entire affected mucosa without removing tissue, preserving oral function while targeting dysplastic changes. This makes PDT uniquely suited to diffuse oral pre-malignancy.
Clinical Indications for Oral PDT in India
Indian centres have established PDT protocols across four distinct oral indications โ each with different photosensitiser choices, delivery techniques, and outcome expectations.
Oral Leucoplakia (Pre-Malignant White Patches)
Biopsy-confirmed oral leucoplakia with moderate or severe dysplasia is the primary indication. ALA cream is applied to the lesion(s), activated with red light via a fibre or LED device. Complete response rates of 50โ75% at 3 months in published Indian series. Homogeneous leucoplakia responds better than verrucous or non-homogeneous types. Must have biopsy to exclude invasive carcinoma before PDT.
Oral Submucous Fibrosis (OSMF)
OSMF โ caused by areca nut-induced mucosal fibrosis with risk of malignant transformation โ is highly prevalent in India, South and Southeast Asia. PDT targets the dysplastic mucosal changes overlying the fibrotic bands. Studies from Tata Memorial and AIIMS show 40โ65% improvement in mucosal lesions, with function preservation. Multiple PDT sessions are often required.
Early Oral Squamous Cell Carcinoma (T1โT2, Inoperable or Refusing Surgery)
For patients with T1โT2 oral SCC who are medically inoperable or who decline surgery, Photofrin PDT or ALA-PDT offers curative-intent treatment. Complete response rates of 40โ65% in selected patients from Indian series. Requires careful patient selection โ primary surgery or radiation remains standard for operable patients.
Recurrent/Residual Oral Cancer Post-Radiation
Re-irradiation of recurrent oral cancer in a previously irradiated field carries severe toxicity. PDT offers a non-radiation local treatment option for small recurrent oral lesions after prior radiotherapy. Limited published data but an important niche for patients with few remaining options.
Indian Institutional PDT Experience โ Summary
Published outcomes from India's leading oral PDT centres.
| Institution | Primary Oral PDT Focus | Photosensitiser Used | Key Published Outcomes |
|---|---|---|---|
| Tata Memorial Hospital, Mumbai | Oral leucoplakia, early oral SCC, OSMF | ALA topical; Photofrin IV for early SCC | Large series; 50โ75% CR for leucoplakia; function preservation reported |
| AIIMS Delhi | Oral leucoplakia, oral submucous fibrosis, recurrent oral cancers | ALA topical; selected Photofrin | OSMF outcomes series; pre-malignant lesion PDT protocols published |
| Regional Cancer Centre, Thiruvananthapuram | Oral pre-malignancy in high-prevalence South Indian population | ALA topical | Leucoplakia series in Kerala tobacco/areca nut users |
| Kidwai Memorial Institute of Oncology, Bangalore | Head and neck cancers including oral cavity | Photofrin and ALA | Head and neck PDT series including oral indications |
ALA-PDT Technique for Oral Cavity Lesions
Delivering PDT to the oral cavity requires specific adaptations compared to skin or endoscopic PDT โ the photosensitiser is applied directly to the oral mucosa, and light delivery uses an intraoral device.
Photosensitiser Application
ALA solution or gel is applied directly to the oral lesion(s) via a cotton-tipped applicator or custom-fit intraoral tray. The lesion is kept moist and undisturbed for 3โ4 hours. Patients avoid eating, drinking, or rinsing during the incubation period. Some protocols use a removable dental tray filled with ALA gel for field application across larger oral areas.
Intraoral Light Delivery
Red light is delivered intraorally via an optical fibre or small LED device positioned within the oral cavity. For well-defined lesions, a flat-cut fibre tip is positioned above the lesion surface. For diffuse lesions (OSMF, widespread leucoplakia), an intraoral LED device illuminates the entire affected area. Treatment times are 5โ15 minutes depending on light dose.
Post-Treatment Oral Care
Post-PDT oral mucositis (redness, mild ulceration) in the treated area is common for 7โ14 days. Managed with antiseptic mouthwashes (chlorhexidine), analgesic gels, and soft diet. Oral hygiene maintenance is important to prevent secondary infection during the healing phase.
Explore the PDT Knowledge Base
Related PDT topics and resources.
- What Is Photodynamic Therapy and How Does It Work?
- Photofrin (Porfimer Sodium): The Most Widely Approved Photosensitiser
- ALA and Methyl-ALA: Topical Photosensitisers for Skin Cancer PDT
- Microwave Ablation in India: Centres and Access
- Photodynamic Therapy โ Full Treatment Page
- Oral Cancer โ Condition Page
Frequently Asked Questions
Common questions about oral PDT in India.
About the Treatment
Can PDT permanently cure oral leucoplakia?
PDT can achieve complete clearance of oral leucoplakia in 50โ75% of patients at 3 months. However, leucoplakia is driven by ongoing mucosal damage from tobacco, areca nut, or other carcinogens โ which may not stop after treatment. Many patients experience lesion recurrence months to years after initially successful PDT. Cessation of the underlying cause (stopping tobacco and areca nut use) is essential for durable benefit. PDT is a treatment for the lesion; cessation counselling treats the cause.
How many PDT sessions are needed for oral leucoplakia?
Most protocols involve 1โ3 sessions spaced 4โ6 weeks apart depending on response. Extensive or thick leucoplakia may require more sessions. Some patients with OSMF require 4โ6 or more sessions across a longer treatment period. Response is assessed between sessions and the plan adjusted accordingly.
Access in India
Can international patients access oral PDT at Tata Memorial or AIIMS?
Yes. Both Tata Memorial Hospital and AIIMS accept international patients, though processes differ. Tata Memorial has a dedicated international patient service. AIIMS is a public institution with a more complex international patient pathway. CancerFax can facilitate pre-screening and logistics for international patients accessing oral PDT at these centres or at other experienced Indian institutions.
How does oral PDT cost in India?
ALA-PDT for oral leucoplakia at Indian academic centres typically costs $500โ$2,000 per session depending on the institution, lesion extent, and whether multiple lesions are treated simultaneously. Photofrin IV-PDT for early oral SCC is higher โ $2,000โ$5,000 per session at private centres; substantially less at public institutions. Multiple sessions are typically needed, so total treatment cost ranges $2,000โ$10,000 depending on indication and extent.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Oral Leucoplakia, OSMF, or Early Oral Cancer? Indian PDT Centres May Help.
Upload your biopsy reports, oral examination photos, and medical history. Our head and neck oncology team will assess whether PDT is appropriate and identify the right Indian centre for your case.
For informational purposes only. Oral PDT suitability requires biopsy confirmation and evaluation by qualified head and neck oncology specialists. Cessation of tobacco, areca nut, and betel quid is essential alongside any treatment.